New interesting findings for the tumor marker UBC® Rapid | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

March 2016

New interesting findings for the tumor marker UBC® Rapid

Result from a new German multicenter study

At this year’s EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on UBC® Rapid was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital, Department of Urology, Bad Sarrow. Urine samples were analyzed by UBC®Rapid POC test and evaluated quantitatively. The study showed very high sensitivity and specificity for high grade tumors generally 71/94%, and for CIS patients the sensitivity was even higher 87%.The authors concluded that UBC® Rapid should be added in the diagnostics for high risk bladder cancer and in particular for CIS patients with tumors in the bladder.

 

Annual meeting/Årsstämma

Årsstämma hålls den 27 maj 2020 kl. 15.00 på Piperska Muren, Scheelegatan 14, 112 28 Stockholm.

IDL Biotech signs new distribution agreement with Beckman Coulter, which gives the distributor global sales rights for the company's tumor markers on the ELISA manual platform.

Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, ”says Charlotte Berg, CEO of IDL Biotech. IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.

IDL Biotech

Skip this intro